This clinical trial is focused on studying the long-term safety and tolerability of a treatment called pelacarsen, also known by its code name TQJ230. The study is specifically for patients with cardiovascular disease who have previously participated in a related study. Cardiovascular disease refers to conditions affecting the heart and blood vessels, which can lead to serious health issues like heart attacks or strokes. The treatment involves a solution for injection that is administered using a pre-filled syringe.

The purpose of this study is to evaluate how well patients tolerate the treatment over an extended period. Participants will receive the treatment through injections under the skin, known as subcutaneous use. The study will monitor any adverse effects or serious adverse events, as well as changes in laboratory evaluations and vital signs. The study will also track the number of lipoprotein apheresis sessions, a procedure that removes certain fats from the blood, performed each year for up to five years.

Throughout the study, the levels of a specific type of fat in the blood, known as Lp(a), will be measured at various intervals to see how they change compared to the start of the previous study. This will help researchers understand the long-term impact of pelacarsen on cardiovascular health. Participants in this study have already completed a prior study and are considered safe to continue by their healthcare provider. The study aims to provide valuable information on the safety of pelacarsen for individuals with cardiovascular disease.